(RXL) ProShares Ultra Health Care - Ratings and Ratios
Biotech, Pharmaceuticals, Medical Devices, Health Services
Dividends
| Dividend Yield | 1.68% |
| Yield on Cost 5y | 1.92% |
| Yield CAGR 5y | 61.42% |
| Payout Consistency | 79.8% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 25.1% |
| Value at Risk 5%th | 41.3% |
| Relative Tail Risk | 0.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.42 |
| Alpha | -0.76 |
| CAGR/Max DD | 0.21 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.394 |
| Beta | 0.983 |
| Beta Downside | 0.973 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.07% |
| Mean DD | 11.94% |
| Median DD | 9.48% |
Description: RXL ProShares Ultra Health Care January 05, 2026
ProShares Ultra Health Care (NYSE ARCA:RXL) is a leveraged equity ETF that seeks daily returns equal to twice the performance of an index tracking S&P 500 health-care constituents. The fund achieves this by holding leveraged exposure-typically at least 80% of assets-in the underlying health-care stocks or comparable instruments, and it is classified as a non-diversified, high-volatility vehicle.
Key market facts: the ETF trades with a 2× leverage factor and carries an expense ratio of roughly 0.35%, which is modest for a leveraged product. The health-care sector has been driven by an aging U.S. population and rising Medicare enrollment, supporting a recent 5-6% annual earnings growth rate across the S&P 500 health-care companies. Additionally, biotech R&D spending, which has climbed over 8% YoY, fuels pipeline expansion and can amplify price moves that leveraged funds like RXL amplify.
If you want a data-driven, risk-adjusted deep-dive on RXL’s performance metrics, consider checking the analytics on ValueRay.
What is the price of RXL shares?
Over the past week, the price has changed by +3.49%, over one month by +2.08%, over three months by +15.47% and over the past year by +8.74%.
Is RXL a buy, sell or hold?
What are the forecasts/targets for the RXL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 55.8 | 3.6% |
RXL Fundamental Data Overview January 27, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 90.7m USD (90.7m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 90.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 90.7m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.54% (E(90.7m)/V(90.7m) * Re(9.54%) + (debt-free company))
Discount Rate = 9.54% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for RXL ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle